Mast Therapeutics (MSTX) Announces Vepoloxamer Data Selected For Presentation at ASH Meeting
- Nasdaq ends down as investors eye Black Friday sales, China infections
- Apple (AAPL) could see a $6B hole in FQ1 iPhone revenue due to Foxconn troubles - analyst
- Activision Blizzard (ATVI) slips on report FTC likely to oppose $69B Microsoft (MSFT) deal
- Manchester United (MANU) shares jump again on Saudi interest
- Bitcoin (BTC) price struggles to rebound as Binance launches $1 billion recovery fund
Mast Therapeutics (NYSE: MSTX) today announced that data from nonclinical studies investigating vepoloxamer, its lead product candidate, will be featured in three poster sessions at the 57th Annual American Society of Hematology (ASH) Meeting and Exposition. The ASH Meeting is being held at the Orange County Convention Center in Orlando, Florida, December 5 through December 8, 2015.
The studies to be presented demonstrate the anti-adhesive effects of vepoloxamer on sickle red blood cells (RBC) as well as its protective effects on the membranes of red blood cells and platelets. In one study, vepoloxamer was shown to result in statistically significant reductions in the number of adherent sickle RBC to immobilized vascular cell adhesion molecule (VCAM) and reductions in hemolysis in blood from patients with sickle cell disease (SCD) (n=12). In other studies, vepoloxamer was shown to preserve platelet function under extended storage conditions as well as prevent exposure of a marker of platelet damage (phosphatidyl serine) in blood samples from patients with SCD.
Dr. R. Martin Emanuele, Senior Vice President, Development, said: "These results are encouraging since they continue to demonstrate vepoloxamer's membrane protecting effects. Protecting the integrity of RBC and platelet membranes may be an important treatment goal in several clinical conditions but especially in sickle cell disease where hemolysis and platelet thrombosis are well known to be associated with worsening outcomes."
- A poster entitled "Evaluation of Purified Poloxamer -188 (vepoloxamer) on Sickle Red Blood Cell (RBC) Membrane Function Properties," will be presented by Dr. Jennell White on December 6, 2015 as part of the Hemoglobinopathies, Excluding Thalassemia – Clinical Program, Oral and Poster Abstracts Session: 114 in Hall A, Level 2.
- A poster entitled "Functional Protection of Platelets By Tri-Block Polymer (Poloxamer-188) As Studied in Agonist Induced Platelet Aggregation Systems," will be presented by Dr. Nil Guler on December 5, 2015 as part of the Platelet Activation and Biochemistry Program: Oral and Poster Abstracts Session: 301 in Hall A, Level 2.
- A poster entitled "Characterizing Cellular Interactions Contributing to Vaso-Occlusion in Patients with Sickle Cell Disease Utilizing a Novel Endothelialized Microfluidic Device," will be presented by Dr. Margo Rollins on December 7, 2015 as part of the Hemoglobinopathies, Excluding Thalassemia – Basic and Translational Science Program: Oral and Poster Abstracts Session: 113 in Hall A, Level 2.
- Copies of the posters will be available concurrent with the presentations on the Company's website at: http://www.masttherapeutics.com/technology/publications/
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- VinFast ships 999 electric vehicles to U.S.
- Veris Residential, Inc (VRE) Says $16.00 per Share Offer From Kushner Grossly Undervalues Company
- CN Energy Group (CNEY) has Upgraded its 6G Gasification Reactors
Create E-mail Alert Related CategoriesCorporate News, FDA, Management Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!